QIAGEN Announces First-ever Regulatory Registration of a Lung Cancer Companion Diagnostic Based on L
QIAGEN Announces First-ever Regulatory Registration of a Lung Cancer Companion Diagnostic Based on Liquid Biopsies in Collaboration With AstraZeneca
3 Clinical-Stage Biotech Stocks with Explosive Upside Potential in 2015
Clinical-stage biotechs tend to bubble to the top of the list of best performing healthcare stocks. Here are three names to watch in 2015 and beyond.
I Think This Next-Generation Diabetes Drug Offers the Greatest Growth Potential
Three Motley Fool analysts weigh in with the companies they think could benefit from launching next generation diabetes treatments.
Does AstraZeneca PLC Stock Offer a Golden Opportunity in 2015?
AstraZeneca would appear to be set to have a slow 2015. But that doesn't mean investors should sleep on this stock. Here's why.
History Suggests MannKind Corporation's Afrezza Could Already Be Doomed
Afrezza could be a game-changing inhaled diabetes therapy, but it must overcome an obstacle that crushed previous potential game changers.
Is AbbVie Inc. Ripe for a Buyout?
After failing to complete a buyout of Irish biopharma Shire, AbbVie was reported to be a potential takeover target. Is this top drugmaker an attractive acquisition target for growth-starved big pharma in 2015?